Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific Buys Atritech For Watchman Stroke Prevention Device

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific will acquire the Watchman minimally invasive stroke-prevention device for patients with atrial fibrillation through its Jan. 19 purchase of Atritech for up to $375 million.

You may also be interested in...

Boston Sci’s Watchman Stroke Device Finally Lands FDA Approval, With Favorable Labeling

Three separate FDA advisory panels examined the clinical data supporting the left-atrial appendage closure device and struggled to identify exactly which patients it benefits. But FDA has finally approved Watchman with an indication that analysts say will support meaningful market action for Boston Scientific. Reimbursement policies, however, remain a question mark.

Third Panel’s The Charm For Watchman? More Delays For Boston Sci’s Stroke Device

FDA has requested that a PMA for Boston Scientific’s Watchman left atrial appendage closure device for stroke-prevention be subject to another advisory panel meeting -- the third since 2009 -- which will delay the launch to, at earliest, the first half of 2015, the company says.

Report From HRS: PROTECT AF Positive For Watchman

Boston Scientific is highlighting a secondary-endpoint analysis showing that the left atrial appendage closure device reduced all-cause death by 34%. The company plans to submit a PMA for the device by the end of the second quarter.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts